LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data.
Patients' preferences for adjuvant sorafenib after resection of intermediate or high-risk renal cell carcinoma in the SORCE trial: What makes it worthwhile? This is an ASCO Meeting Abstract from the ...
Partial and radical nephrectomy for T3a RCC have similar 5-year rates of overall and cancer-specific survival, according to a propensity score-matched analysis. WASHINGTON, DC—Partial nephrectomy (PN) ...
Patients with low-stage renal cell carcinoma (RCC) are increasingly treated with minimally invasive therapies, to reduce treatment-related morbidity. Pathological information, however, is limited with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results